New drug duo tested in fight against tough lung cancers
NCT ID NCT04250545
Summary
This early-stage trial is testing a combination of two oral drugs, sapanisertib and telaglenastat, in patients with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to check for side effects. The drugs aim to work together to block pathways that cancer cells use to grow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
-
Keck Medicine of USC Koreatown
Los Angeles, California, 90020, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.